India · Delayed Price · Currency is INR NSE:NEPHROPLUS Statistics
Total Valuation
NSE:NEPHROPLUS has a market cap or net worth of INR 62.40 billion. The enterprise value is 58.79 billion.
| Market Cap | 62.40B |
| Enterprise Value | 58.79B |
Important Dates
The last earnings date was Tuesday, November 3, 2026.
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NSE:NEPHROPLUS has 100.56 million shares outstanding.
| Current Share Class | 100.56M |
| Shares Outstanding | 100.56M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.35% |
| Owned by Insiders (%) | 14.71% |
| Owned by Institutions (%) | 24.21% |
| Float | 28.59M |
Valuation Ratios
The trailing PE ratio is 48.90 and the forward PE ratio is 38.00. NSE:NEPHROPLUS's PEG ratio is 1.01.
| PE Ratio | 48.90 |
| Forward PE | 38.00 |
| PS Ratio | 5.62 |
| PB Ratio | 5.25 |
| P/TBV Ratio | 6.37 |
| P/FCF Ratio | 32.99 |
| P/OCF Ratio | 21.98 |
| PEG Ratio | 1.01 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 24.83, with an EV/FCF ratio of 31.08.
| EV / Earnings | 45.89 |
| EV / Sales | 5.29 |
| EV / EBITDA | 24.83 |
| EV / EBIT | 42.34 |
| EV / FCF | 31.08 |
Financial Position
The company has a current ratio of 2.42, with a Debt / Equity ratio of 0.13.
| Current Ratio | 2.42 |
| Quick Ratio | 2.21 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | 0.60 |
| Debt / FCF | 0.79 |
| Interest Coverage | 12.27 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 15.76% |
| Return on Capital Employed (ROCE) | 11.91% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 4.84M |
| Profits Per Employee | 558,487 |
| Employee Count | 2,294 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, NSE:NEPHROPLUS has paid 229.06 million in taxes.
| Income Tax | 229.06M |
| Effective Tax Rate | 15.17% |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 661.46 |
| 200-Day Moving Average | 623.48 |
| Relative Strength Index (RSI) | 46.93 |
| Average Volume (20 Days) | 124,080 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NSE:NEPHROPLUS had revenue of INR 11.10 billion and earned 1.28 billion in profits. Earnings per share was 12.69.
| Revenue | 11.10B |
| Gross Profit | 4.36B |
| Operating Income | 1.49B |
| Pretax Income | 1.51B |
| Net Income | 1.28B |
| EBITDA | 2.34B |
| EBIT | 1.49B |
| Earnings Per Share (EPS) | 12.69 |
Balance Sheet
The company has 5.10 billion in cash and 1.49 billion in debt, with a net cash position of 3.61 billion or 35.93 per share.
| Cash & Cash Equivalents | 5.10B |
| Total Debt | 1.49B |
| Net Cash | 3.61B |
| Net Cash Per Share | 35.93 |
| Equity (Book Value) | 11.89B |
| Book Value Per Share | 118.43 |
| Working Capital | 5.38B |
Cash Flow
In the last 12 months, operating cash flow was 2.84 billion and capital expenditures -947.81 million, giving a free cash flow of 1.89 billion.
| Operating Cash Flow | 2.84B |
| Capital Expenditures | -947.81M |
| Depreciation & Amortization | 844.64M |
| Net Borrowing | -1.41B |
| Free Cash Flow | 1.89B |
| FCF Per Share | 18.81 |
Margins
Gross margin is 39.31%, with operating and profit margins of 13.45% and 11.54%.
| Gross Margin | 39.31% |
| Operating Margin | 13.45% |
| Pretax Margin | 13.60% |
| Profit Margin | 11.54% |
| EBITDA Margin | 21.06% |
| EBIT Margin | 13.45% |
| FCF Margin | 16.96% |
Dividends & Yields
NSE:NEPHROPLUS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | 2.04% |
| FCF Yield | 3.03% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Analyst Forecast
The average price target for NSE:NEPHROPLUS is 798.00, which is 28.60% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 798.00 |
| Price Target Difference | 28.60% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 19.97% |
| EPS Growth Forecast (3Y) | 42.27% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |